Telix to buy radiopharma rival ITM for $1.65bn upfront
Telix to buy radiopharma rival ITM for $1.65bn upfront
Telix Pharmaceuticals
Radiopharmaceutical company developing imaging and therapeutic products for oncology, including PSMA-PET imaging agent Illuccix and the late-stage kidney cancer imaging agent TLX250-CDx; acquiring ITM Isotope Technologies Munich to add a therapeutic pipeline and isotope supply network.
Company Info
Upcoming Milestones & Key Dates
2026
M&A
Close of $1.65B ITM Isotope Technologies Munich acquisition
Clinical Development Pipeline
Illuccix (gallium-68 PSMA-11)
Target: PSMATLX250-CDx (zirconium-89 girentuximab)
Target: CAIXITM-11 (lutetium-177 edotreotide)
Target: Somatostatin receptorRecent News
Telix beams into Novartis' territory with $1.6B ITM acquisition
Telix struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis' Lutathera and a radiopharmaceutical supply network; analysts called the move 'extremely bullish'.
Leadership Team
Christian Behrenbruch
Group Chief Executive Officer
Kevin Richardson
Chief Executive Officer, Telix Therapeutics
Richard Valeix
Chief Executive Officer, Telix International